ARL 100
Latest Information Update: 16 Jul 2002
At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Anti-ischaemics; Cardiotonics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 30 May 1997 No-Development-Reported for Ischaemic heart disorders (Unknown route)